Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Low Blood Absolute CD4 Counts Is Associated with Inferior Progression Free Survival in Diffuse Large B-Cell Lymphoma Independent of Age and IPI

Tahseen I. Al-Saleem, MD, Essel Dulaimi, MD, Michael M. Millenson, MD, Mitchell R. Smith, MD PhD, Julia Judd, Tianyu Li, Hossein Borghaei, DO, MS

Blood (2014) 124 (21): 5420.

https://doi.org/10.1182/blood.V124.21.5420.5420

Published: 2014

Journal Articles

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Hossein Borghaei, DO, MS, Russell J. Schilder, MD, Samuel Litwin, PhD, Michael Millenson, MD, Adam D Cohen, MD, Linda Thibodeau, RN, Mitchell R Smith, MD, PhD

Blood (2012) 120 (21): 2753.

https://doi.org/10.1182/blood.V120.21.2753.2753

Published: 2012

Journal Articles

Assessing CD137 (4-1BB) As a Therapeutic Target in B-Cell Neoplasms,

Adam D Cohen, MD, Indira D Joshi, Ph.D., Valentin Robu, MD, Hossein Borghaei, DO, Tahseen I. Al-Saleem, MD, Maria Jure-Kunkel, Mitchell R Smith, MD, PhD

Blood (2011) 118 (21): 3735.

https://doi.org/10.1182/blood.V118.21.3735.3735

Published: 2011

Journal Articles

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

Razelle Kurzrock, MD, Peter M. Voorhees, MD, Corey Casper, MD, Richard R. Furman, MD, Luis Fayad, MD, Sagar Lonial, MD, Hossein Borghaei, DO, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Saad Usmani, MD, FACP, Helgi van de Velde, MD, PhD, Xiang Qin, PhD, Ming Qi, MD, PhD, Mark J. Cornfeld, MD, MPH, Frits van Rhee, MD, PhD

Blood (2011) 118 (21): 3959.

https://doi.org/10.1182/blood.V118.21.3959.3959

Published: 2011

Journal Articles

Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens

Andre Goy, MD, Barbara Pro, MD, Kerry Joanne Savage, MD, BSc, MSc, Nancy L. Bartlett, MD, Mary Jo Lechowicz, MD, Eric D Jacobsen, MD, Faith Young, Michael Crump, MD, FRCPC, Hossein Borghaei, DO, Brian Link, Steven M. Fruchtman, MD, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 1753.

https://doi.org/10.1182/blood.V116.21.1753.1753

Published: 2010

Journal Articles

CD4 Cell Count of More Than 250/Microl in the Peripheral Blood Is Associated with Improved Overall Survival in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Independent of the aaIPI

Hossein Borghaei, DO, MS, Mitchell Smith, MD, Ph.D., Michael Millenson, Tianyu Li, Danielle Shafer, DO, Tahseen I. Al-Saleem, MD

Blood (2008) 112 (11): 3775.

https://doi.org/10.1182/blood.V112.11.3775.3775

Published: 2008

Journal Articles

CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study.

Frits Van Rhee, MD, PhD, Luis Fayad, MD, Peter Voorhees, MD, Richard R Furman, MD, Hossein Borghaei, DO, MS, Sagar Lonial, MD, Lubomir Sokol, MD, PhD, Julie Crawford, BS, Mark Cornfeld, MD, MPH, Ming Qi, MD, PhD, Jennifer Herring, RN, Xiang Qin, MS, Razelle Kurzrock, MD

Blood (2008) 112 (11): 1008.

https://doi.org/10.1182/blood.V112.11.1008.1008

Published: 2008

Journal Articles

A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.

Razelle Kurzrock, MD, Luis Fayad, Peter Voorhees, MD, Richard R Furman, MD, Sagar Lonial, MD, Hossein Borghaei, DO, MS, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Mark Cornfeld, MD, MPH, Ming Qi, MD, PhD, Trina Jiao, MS, Jennifer Herring, RN, Xiang Qin, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 1009.

https://doi.org/10.1182/blood.V112.11.1009.1009

Published: 2008

Journal Articles

Peripheral Blood CD3 + CD4 + and CD3 − CD56 + Cell Counts and Circulating Lymphoma Cells Are Significant Predictors of Overall Survival in Newly Diagnosed Follicular Lymphoma.

Danielle Shafer, DO, Mitchell R. Smith, MD, PhD, Samuel Litwin, PhD, Tianyu Li, Hossein Borghaei, DO, Tahseen I. Al-Saleem, MD

Blood (2007) 110 (11): 2607.

https://doi.org/10.1182/blood.V110.11.2607.2607

Published: 2007

Journal Articles

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan (Zevalin) and Gemicitabine in Patients with Non-Hodgkin’s Lymphoma.

Hossein Borghaei, DO, MS, Mitchell R. Smith, MD, Ph.D., Michael Millenson, MD, Linda Thibodeau, RN, Nicole Kamiensky, Russell J. Schilder, MD

Blood (2007) 110 (11): 4485.

https://doi.org/10.1182/blood.V110.11.4485.4485

Published: 2007

Journal Articles

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma.

Hossein Borghaei, DO, MS, Mitchell Smith, MD, Ph.D., Michael Millenson, MD, Danielle Shafer, DO, Linda Thibodeau, RN, Russell Schilder, MD

Blood (2006) 108 (11): 4710.

https://doi.org/10.1182/blood.V108.11.4710.4710

Published: 2006

Journal Articles

Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells.

Liat Binyamin, PhD, R. Katherine Alpaugh, Ph.D, Kerry S. Campbell, Ph.D, Hossein Borghaei, DO, MS, Louis M. Weiner, MD

Blood (2005) 106 (11): 2456.

https://doi.org/10.1182/blood.V106.11.2456.2456

Published: 2005

Journal Articles

Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkins’s Lymphoma: Long Term Follow-Up.

Danielle Shafer, DO, Hossein Borghaei, DO, Michael Millenson, MD, Nicos Nicolaou, MD, Tahseen I. Al-Saleem, MD, Nick C. Leasure, MD, Kris Padavic, RN, Mitchell R. Smith, MD, PhD, Russell J. Schilder, MD

Blood (2005) 106 (11): 2677.

https://doi.org/10.1182/blood.V106.11.2677.2677

Published: 2005

NARROW

Low Blood Absolute CD4 Counts Is Associated with Inferior Progression Free Survival in Diffuse Large B-Cell Lymphoma Independent of Age and IPI

Phase I Trial of Combination Therapy with 90 y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.

Assessing CD137 (4-1BB) As a Therapeutic Target in B-Cell Neoplasms,

Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease,

Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens

CD4 Cell Count of More Than 250/Microl in the Peripheral Blood Is Associated with Improved Overall Survival in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Independent of the aaIPI

CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study.

A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.

Peripheral Blood CD3 + CD4 + and CD3 − CD56 + Cell Counts and Circulating Lymphoma Cells Are Significant Predictors of Overall Survival in Newly Diagnosed Follicular Lymphoma.

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan (Zevalin) and Gemicitabine in Patients with Non-Hodgkin’s Lymphoma.

Phase I Trial of Combination Therapy with 90 Y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin’s Lymphoma.

Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells.

Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkins’s Lymphoma: Long Term Follow-Up.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only